Daiichi Sankyo Company, , an innovative global healthcare company, has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as chief executive officer (CEO), effective April 1, 2025. Dr ...

Revenue growth was fueled by oncology products, particularly ENHERTU, which retained leading market shares in the US, Europe ... Datroway’s shortfall. Daiichi Sankyo’s Q3 FY2024 results ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators ... AstraZeneca and Daiichii Sankyo’s antibody-drug conjugate (ADC) Datroway ...

TOKYO, January 31, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO ...

Europe as well as China, I visited all of their sites and I covered almost 90% of the employees in terms of market reach and explain with my own words the current state of Daiichi Sankyo and the ...

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025. Dr. Manabe will ...

TOKYO, January 31, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective ...

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Thursday recommended approval for AstraZeneca and Daiichi Sankyo's TROP2-directed antibody drug ...

Daiichi Sankyo’s board of directors followed the nomination committee’s report in making the appointment. Credit: ArDanMe/Shutterstock. Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed ...